Search Result

Results for "

CBP histone acetyltransferase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Histone Acetyltransferase (18) Epigenetic Reader Domain (3) MDM-2/p53 (1) PROTACs (1)
By Research Areas:	Cancer (19) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (5)

Targets Recommended: Histone Acetyltransferase Histone Methyltransferase Histone Demethylase HDAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-128876

CBP/p300-IN-3	Histone Acetyltransferase	Cancer
CBP/p300-IN-3, a p300/CBP **histone acetyltransferase** inhibitor, Compound 6, is sourced from patent WO 2019049061 A1 .

HY-107455

A-485 Maximum Cited Publications 53 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
A-485 is a potent and selective catalytic inhibitor of *p300/CBP* with IC₅₀s of 9.8 nM and 2.6 nM for p300 and *CBP* histone acetyltransferase (HAT), respectively .

HY-136285

CPI-1612	Histone Acetyltransferase	Cancer
CPI-1612 is a highly potent, orally active *EP300/CBP* histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT**. CPI-1612 has an anticancer activity .

HY-128875

CBP/p300-IN-10	Histone Acetyltransferase	Cancer
CBP/p300-IN-10 is a highly potent histone acetyltransferase EP300 and CREBBP with IC₅₀ values of 26 nM and 39 nM, respectively. CBP/p300-IN-10 can be used to research anticancer .

HY-139149

NiCur	Histone Acetyltransferase	Cancer
NiCur is a potent and selective CBP histone acetyltransferase (HAT) inhibitor with an IC₅₀ value of 0.35 μΜ. NiCur, which blocks CBP HAT activity and downregulates p53 activation upon genotoxic stress. NiCur can be used for performing mechanistic studies without affecting the expression of target proteins .

HY-139149A

(E/Z)-NiCur	Histone Acetyltransferase	Cancer
(E/Z)-NiCur is the active isomer of NiCur (HY-139149). (E/Z)-NiCur is a potent CBP histone acetyltransferase (HAT) inhibitor .

HY-147261

B026	Histone Acetyltransferase	Cancer
B026 is a selective, potent, orally active *p300/CBP* histone acetyltransferase (HAT) inhibitor with IC₅₀** values of 1.8 nM and 9.5 nM for p300 and CBP enzyme, respectively. B026 has anticancer activity for androgen receptor-positive (AR+) prostate cancer cell lines .

HY-168201

MJP6412	PROTACs Histone Acetyltransferase	Cancer
MJP6412 is a potent degrader histone acetyltransferases *p300/CBP, with DC₅₀* of 1.6 and 1.2 nM for p300 and CBP, respectively. MJP6412 plays an important role in cancer research .

HY-100132

CBP/p300-IN-5	Histone Acetyltransferase	Cancer
P300/CBP-IN-5 is a potent p300/CBP histone acetyltransferase inhibitor extracted from patent WO2016044770A1, Example 715, has an IC₅₀ of 18.8 nM .

HY-161483

CBP/p300 ligand 3	Epigenetic Reader Domain Histone Acetyltransferase	Neurological Disease Cancer
CBP/p300 ligand 3 is a target protein ligand of CBPD-268 (HY-161369). *CBP* and p300 are two proteins with histone acetyltransferase (HAT) activity, and *CBP* and p300 play key roles in regulating biological processes such as gene expression, cell proliferation, differentiation and DNA repair. Through its acetyltransferase activity, *CBP/p300* can acetylate histones and other proteins, thereby regulating chromatin structure and gene expression. CBP/p300 ligand 3 regulates the function of *CBP/p300* by binding to a specific domain of the *CBP/p300* protein (the bromine domain or HAT domain), inhibiting its enzyme activity or altering its interactions with other proteins (transcription factors). CBP/p300 ligand 3 can be used in cancer, neurodegenerative diseases and other disease models associated with abnormal *CBP/p300* function .

HY-132197

CBP/p300-IN-12 1 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-12 is a potent and selective covalent histone acetyltransferases p300 (IC₅₀ of 166 nM) and *CBP* inhibitor. CBP/p300-IN-12 decreases the levels of H3K27Ac of PC-3 cells (EC₅₀ of 37 nM). CBP/p300-IN-12 forms a covalent adduct with C1450 .

HY-149306

MS78	Histone Acetyltransferase MDM-2/p53	Cancer
MS78 is an acetylation targeting chimera (AceTAC) that acetylates the p53 tumor suppressor protein. MS78 recruits histone acetyltransferase *p300/CBP* to acetylate the p53Y220C mutant. MS78 upregulates TRAIL apoptotic genes and downregulates DNA damage response pathways. MS78 contains a CBP/p300 binder, a p53Y220C binder and a linker .

HY-124696

PU139 3 Publications Verification	Histone Acetyltransferase	Cancer
PU139 is a potent pan-histone acetyltransferase (HAT) inhibitor. PU139 blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB (cAMP response element-binding) protein (CBP) and p300 with IC₅₀s of 8.39, 9.74, 2.49 and 5.35 μM, respectively .

HY-145386

(S,S)-CPI-1612	Others	Cancer
(S,S)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active *EP300/CBP* histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT**. CPI-1612 has an anticancer activity .

HY-136285A

(R,R)-CPI-1612	Others	Cancer
(R,R)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active *EP300/CBP* histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT**. CPI-1612 has an anticancer activity .

HY-147290

NSC 694623	Histone Acetyltransferase	Cancer
NSC 694623 is a potent histone acetyltransferase (HAT) inhibitor with an IC₅₀ value of 15.9 μM for recombinant HAT p300/CBP-associated factor (PCAF). NSC 694623 has antiproliferative activity against certain cancer cells. NSC 694623 can be used for researching anticancer .

HY-16531

YF-2 2 Publications Verification	Histone Acetyltransferase	Neurological Disease Cancer
YF-2 is a highly selective, blood-brain-barrier permeable **histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC₅₀*s of 2.75 μM, 29.04 μM and 49.31 μM for CBP*, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer's disease .

HY-16531A

YF-2 hydrochloride 2 Publications Verification	Histone Acetyltransferase	Neurological Disease Cancer
YF-2 hydrochloride is a highly selective, blood-brain-barrier permeable **histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC₅₀*s of 2.75 μM, 29.04 μM and 49.31 μM for CBP*, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer's disease .

HY-129039

Butyrolactone 3 5+ Cited Publications MB-3	Histone Acetyltransferase	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Butyrolactone 3 (MB-3) is a specifical small-molecule inhibitor of the histone acetyltransferase Gcn5 (IC₅₀=100 μM), which has a high affinity to the Gcn5 enzyme comparable to that of its natural substrate, histone H3. Butyrolactone 3 shows weak inhibitory on *CBP* (IC₅₀=0.5 mM). Butyrolactone 3 can be used in studies of cancer, metabolic, autoimmune and neurological diseases .

HY-116673

TTK21	Histone Acetyltransferase	Neurological Disease
TTK21 is an activator of the histone acetyltransferases *CBP/p300. TTK21 passes the blood–brain barrier, induces no toxicity, and reaches different parts of the brain when conjugated to glucose-based carbon nanosphere (CSP). TTK21 has beneficial implications for the brain functions of neurogenesis and long-term memory .CSP-TTK21 can ameliorate Aβ-impaired long-term potentiation (LTP). CSP-TTK21 may enhance the transcription of genes that promote synaptic health and cognitive function . CSP-TTK21 is orally effective and leads to improvements in motor functions, histone* acetylation dynamics in a spinal injury rat model .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

CBP histone acetyltransferase

Inhibitors & Agonists